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Abstract
Introduction: GH induces acute insulin resistance in skeletal muscle in vivo, which in rodent models has been attributed to
crosstalk between GH and insulin signaling pathways. Our objective was to characterize time course changes in signaling
pathways for GH and insulin in human skeletal muscle in vivo following GH exposure in the presence and absence of an oral
glucose load.
Methods: Eight young men were studied in a single-blinded randomized crossover design on 3 occasions: 1) after an
intravenous GH bolus 2) after an intravenous GH bolus plus an oral glucose load (OGTT), and 3) after intravenous saline plus
OGTT. Muscle biopsies were taken at t=0, 30, 60, and 120. Blood was sampled at frequent intervals for assessment of GH,
insulin, glucose, and free fatty acids (FFA).
Results: GH increased AUCglucose after an OGTT (p,0.05) without significant changes in serum insulin levels. GH induced
phosphorylation of STAT5 independently of the OGTT. Conversely, the OGTT induced acute phosphorylation of the insulin
signaling proteins Akt (ser
473 and thr
308), and AS160.The combination of OGTT and GH suppressed Akt activation, whereas
the downstream expression of AS160 was amplified by GH.
We Concluded the Following: 1) A physiological GH bolus activates STAT5 signaling pathways in skeletal muscle
irrespective of ambient glucose and insulin levels 2) Insulin resistance induced by GH occurs without a distinct suppression
of insulin signaling proteins 3) The accentuation of the glucose-stimulated activation of AS 160 by GH does however
indicate a potential crosstalk between insulin and GH.
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Introduction
Growth hormone (GH) promotes longitudinal growth and
somatic maturation in children and adolescents and is also an
important regulator of substrate metabolism and insulin sensitivity
[1]. In the post-absorptive phase, where endogenous GH secretion
is stimulated, GH promotes lipolysis and oxidation of fatty acids at
the expense of glucose [2,3]. This insulin-antagonistic effect is
accentuated during more prolonged fasting and may constitute a
favorable protein-saving mechanism due to impeded demand for
gluconeogenesis from amino acids [4–6]. On the other hand,
sustained GH elevations in non-fasting conditions, as seen in
acromegaly, may result in glucose intolerance, and manifest
diabetes mellitus [7,8].
The molecular mechanisms by which GH causes insulin
resistance are unclear. Insulin-stimulated glucose transport into
skeletal muscle depends on the activation of a signaling cascade
involving insulin receptor substrate 1 (IRS-1), the phosphatidylino-
sitol 3-kinase, Akt, and Akt substrate of 160 kDa (AS160) [9]. The
entirety of the signaling cascade is not yet known and may include
additional proteins. However, it is well known that insulin signaling
ultimately promotes translocation of the glucose transporter
GLUT4 to the cell surface. Any step in this cascade is a potential
target for GH, and could involve direct crosstalk between signaling
proteins, or indirect effects via free fatty acids (FFA), a known
inhibitor of insulin receptor signaling inhuman skeletal muscle [10].
The predominant GH signaling cascade comprises activation of
the GHR dimer, phosphorylation of JAK2 and subsequently of
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stSTAT5 [11], but there is also animal and in vitro evidence to
suggest that insulin and GH share post-receptor signaling
pathways [12]. However, a cross-talk between GH and insulin
signaling pathways has not been confirmed in human models in
vivo [13,14]. This may, however, relate to the design of these
studies. First, signaling was assessed in either the basal state, where
insulin activity is minimal [14], or during a euglycemic hyper-
insulinemic glucose clamp [13], which is an unphysiological
condition. Second, only single biopsies were obtained in both
studies, which may be insufficient because of the rapid and
fluctuating nature of the post receptor signaling cascades. Third,
measurement of signaling proteins downstream of Akt has so far
not been performed. It should also be noted that human in vivo
data on the time course of stimulated insulin signaling pathways
after an oral glucose tolerance load have not previously been
reported.
We therefore conducted a study where temporal changes in the
activation of signaling proteins downstream of the receptors for
GH and insulin were assessed in serial muscle biopsies in healthy
human subjects following a physiological GH bolus with and
without a concomitant oral glucose load (OGTT).
Methods
Study protocol and informed consent
The study protocol was approved by The Regional Scientific
Ethics Committee of Denmark (M-20070052) and all participants
gave oral and written informed consent to participate. The study
was conducted in accordance to the Helsinki Declaration.
Subjects
We studied 8 healthy men aged 24.661.8 year (mean 6 SE)
with a mean body mass index of 24.261.2 kgxm
22 in a
randomized, crossover design. Routine blood chemistry including
fasting blood glucose and HbA1c levels were normal in all
participants, none of whom received any medication.
Study design
Each participant was studied on 3 separate occasions in a
randomized fashion (Figure 1): 1) after an intravenous GH bolus
(0.5 mg Genotropin, Miniquick, Pfizer, Inc.)(GH); 2) after a
blinded intravenous GH bolus (0.5 mg) plus an oral glucose load
(75 g) (GH + OGTT); and 3) after a blinded intravenous saline
bolus plus an oral glucose load (OGTT). At least two weeks
elapsed between each study, which was performed after an
overnight fast for 12 hours and with the participants resting in the
supine position.
A catheter was inserted in an antecubital vein in each arm, one
for administration of GH/saline, and one for blood sampling. At
09.00 h (t=0 min) the participants received GH/saline 6OGTT.
Muscle biopsies were obtained at t=0 min (just before the
intervention), t=30 min, t=60 min, t=120 min. The biopsies
were taken from the vastus lateralis muscle with a Bergstro ¨m
biopsy needle under local anesthesia (1% lidocain); a small incision
was made through the skin and muscle sheath 15–20 cm above the
knee. The biopsies were taken in random order two by two,
meaning that the first (t=0 min) and the second (t=30 min) were
taken from the same thigh, and the third (t=60 min) and the
fourth (t=120 min) from the contra lateral thigh. A total amount
of <150 mg of muscle was obtained per biopsy. The tissue was
cleansed from blood (within 10 sec) and snap-frozen in liquid
nitrogen. Muscle biopsies were stored at 280uC until analyzed.
Blood was collected just before the first biopsy (t=0), five min after
(t=5), and every 10 min within the first hour (t=10, 20, 30, 40,
50, 60). After the first hour blood was collected every 30 min until
one hour after the last biopsy (t=90, 120, 150, 180). Plasma
glucose and serum GH were measured at every time point. FFA
was measured every 20 min within the first hour (t=0, 20, 40, 60)
and every 30 min afterwards (t=90,120,150,180). Serum insulin
was measured at 0, 20, 30, 40, 60, 120, 180 min. Body
composition and aerobic exercise capacity (VO2-max) were
assessed after completion of the study by Dual-emission X-ray
absorptiometry and a bicycle ergometer, respectively.
Hormones and metabolites
Plasma glucose was measured immediately in duplicates on two
Beckman Glucoanalyzers (Beckman Instruments, Palo Alto, CA).
Serum insulin and GH were measured using time-resolved
fluoroimmunoassays (TF-IFMA; AutoDELFIA, PerkinElmer,
Turku, Finland), FFA was analyzed by a colorimetric method
using a commercial kit (Wako Chemicals, Neuss, Germany).
Intracellular signal transduction
Muscle biopsies were homogenized as previously described [15].
Western blot: Aliquots of protein were resolved by SDS-PAGE,
and proteins were transferred onto nitrocellulose membranes.
Immunoblotting was performed using primary antibodies as
follows: phosho-STAT5, STAT5, phosho Akt, Akt2, phospho-
Figure 1. Study design. Please refer to the paragraph study design for further details.
doi:10.1371/journal.pone.0019392.g001
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(AS160), all obtained from Cell Signaling (Beverly, MA).
Membranes were incubated with horseradish peroxidase–coupled
secondary antibodies, visualized by BioWest enhanced chemilu-
minescence (UVP LabWorks, Upland, CA) and quantified by the
UVP BioImaging System.
Membranes probed with the phospho-specific antibodies were
stripped in a buffer containing 100 mmolxl
21 2-mercaptoethanol,
0.02 gxml
21 SDS and 62.5 mmolxl
21 Tris–HCl (pH 6.7), and re-
probed with corresponding total antibody. The signal from the
phospho-specific antibodies was related to total protein expression
in the sample. STAT5 protein bands were identified using human
muscle stimulated with GH as positive controls [14].The
remaining bands were identified using insulin stimulated rat
muscle [16]. Phosphorylation of AS160 was identified as insulin
responsive band at approximately 160 kDa using the phospho-Akt
substrate (PAS) antibody (Cell Signaling). This antibody has been
shown to primarily identify AS160 in human skeletal muscle
[17,18] but a potential cross-reaction with the AS160 paralogue
TBC1D1 (,155 kDa) cannot be completely excluded.
Isolation of RNA
Skeletal muscle (20 mg) was homogenized in TriZol reagent
(Gibco BRL, Life Technologies, Roskilde, Denmark). RNA was
quantitated by measuring absorbency at 260 nm and 280 nm and
the Integrity of the RNA was checked by visual inspection of the
two ribosomal RNAs on an ethidium bromide stained agarose gel.
Real-time RT-PCR for mRNA analysis
Reverse transcription was performed using random hexamer
primers as described by the manufacturer (GeneAmp RNA PCR
Kit from Perkin Elmer Cetus, Norwalk, CT). Then, PCR-
mastermix containing the specific primers and Taq DNA
polymerase (HotStar Taq, Quiagen Inc. USA) were added. The
following primers were designed using the primer analysis software
Oligo version 6.64:
IGF1: 59GACAGGGGCTTTTATTTCAAC 39and 59 CTCC-
AGCCTCCTTAGATCAC 39, 117 bp, SOCS1: 59ACACGCA-
CTTCCGCACATTC 39and 59 CGAGGCCATCTTCACGCT-
AAG 39, 209 bp; SOCS2: 59GGTCGAGGCGATCAGTG 39and
59 TCCTTGAAGTCAGTGCGAATC 39, 209 bp; SOCS3: 59C-
GGCCACTTGGACTCTGA 39and 59 GCCCTTTGCGCCCT-
TT 39, 106 bp; b-actin 59 ACGGGGTCACCCACACTGTGC
39 and 59 CTAGAAGCATTTGCGGTGGACGATG 39, 658 bp.
Real time quantization of target gene to ß-actin mRNA was
performed with a SYBR-Green real-time PCR assay using an
ICycler from BioRad. The threshold cycle (Ct) was calculated, and
the relative gene-expression was calculated essentially as described
in the User Bulletin #2, 1997 from Perkin Elmer (Perkin Elmer
Cetus, Norwalk, CT).
Statistics
Data are presented as means 6 SE when normally distributed,
and median (ranges) (25%; 75%) when not. Statistical evaluation
of differences between normally distributed data was performed
with a paired t-test and with Wilcoxon rank sum test when data
were not normally distributed. Time series of serum measurements
and results from Western blots were analyzed by ANOVA for
repeated measurements or by using area under curve (AUC).
Correlation analyses were performed using Person’s correlation
coefficient. A p value,0.05 was considered statistical significant.
Statistical analysis was performed using SPSS version 17.0 for
windows (SPSS, Chicago, IL).
Results
Glucose
A significant difference between the plasma glucose curves
obtained from OGTT+GH vs. OGTT alone was recorded
(ANOVA, p=0.04) (Figure 2a). There also was a statistical
significant difference in AUCglucose ((mmolxl
21xmin
21) [1200641
(OGTT+GH) vs. 1105635 (OGTT) (p=0.04) (Figure 2b)]. More-
over, GH together with an OGTT tended to increase peak levels
of plasma glucose (Cmax) (p=0.06) compared to OGTT alone
(Figure 2a).
Insulin, GH, and FFA
Baseline and glucose-stimulated insulin levels (pmolxl
21) were
not significantly influenced by concomitant GH exposure [Cmax:
281657 (OGTT) vs. 243633 (OGTT+GH) (p=0.39); Tmax
(min): 49611 (OGTT) vs. 61614 (OGTT+GH) (p=0.57)
(Figure 3a)]. No significant difference in insulin patterns as a
Figure 2. Glucose measurements. (A) Plasma levels of glucose.
OGTT, oral glucose tolerance test (75 g glucose). GH, growth hormone
bolus (0.5 mg). Black circles=OGTT + GH, white circles=OGTT, black
triangles=GH. Data are presented as mean 6 SE. Using ANOVA
repeated measurements showed a significant difference between OGTT
and OGTT+GH (p=4) (B) AUC-glucose, area under glucose curve.
P-value is based on paired t-test between area under curve for OGTT
and area under curve for OGTT+GH. Data are presented as mean 6 SE.
There was a significant difference in AUC-glucose between OGTT and
OGTT+GH (p=0.04).
doi:10.1371/journal.pone.0019392.g002
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could be recorded (ANOVA, p=0.51). Likewise, we did not
observe a difference in AUCinsulin ((pmolxl
21xmin
21) between
OGTT and OGTT+GH [2490864769 (OGTT) vs. 2552364633
(OGTT+GH) (p=0.843)]. This suggests that the muscles were
stimulated by equal amounts of insulin in the two situations.
The GH bolus yielded serum GH peak values after 10 min
without any impact of a concomitant OGTT (p=0.81) (Figure 3b).
Likewise, a comparable log-linear decline in serum GH levels was
recorded when comparing GH and GH+OGTT.
GH induced a <60% increase in serum FFA levels after
150 min, which was followed by a gradual decline towards
baseline levels after 3 hours (Figure 3c). This lipolytic effect of GH
was suppressed by the concomitant OGTT as characterized by a
<85% suppression after 120 min and a subsequent increase
towards baseline levels after 3 hours. As expected, OGTT alone
induced a pronounced <90% decrease in serum FFA levels after
120 min followed by a minor increase after 3 hours to a level still
<50% lower than baseline. The degree of FFA suppression was
identical throughout the first 120 min between OGTT and
GH+OGTT assessed by AUCFFA (p=0.083), however the
presence of GH after 120 min caused a reversal of the insulin
suppression of lipolysis which made AUCFFA differ significantly
(p=0.026).
STAT5
GH induced a significant 17.5-fold increase in pSTAT5 (AU)
after 30 min compared to baseline. At 60 min the increase was 16-
fold and at 120 min 3- fold, still significantly increased compared
to baseline [87616 (baseline) vs. 15136415 (30 min) (p=0.014);
vs. 14126254 (60 min) (p=0.002); vs. 275665 (120 min.)
(p=0.027)]. The same pattern was recorded when GH was
combined with OGTT (Figure 4a and 4b). ANOVA for repeated
measurements showed no significant difference in pSTAT5
between GH and GH+OGTT (p=0.64). The OGTT alone did
not impact pSTAT5 (Figure 4a). We did not detect any differences
in total STAT5 expression as a function of either time or
treatment. To summarize, GH induced phosphorylation of
STAT5 independently of the OGTT.
Akt
The OGTT induced a significant increase in phosphorylation of
Akt at ser
473 and thr
308 (AU), which was detectable at 30 min.,
60 min and 120 min compared to baseline (Figure 4a, 4c, and 4d).
A similar pattern was recorded when OGTT was combined with
GH exposure, although the most pronounced increase in
phosphorylation of Akt at ser
473 occurred after 60 min rather
than 30 min and phosphorylation of Akt at thr
308 was significantly
lower at t=30 min (p=0.049) and at t=60 min (p=0.03). By
contrast GH alone did not induce significant changes in
phosphorylation of Akt at either site. Using ANOVA for repeated
measurements we found no statistical significant difference
between the two curves (OGTT and OGTT+GH) for either
Aktser
473 (p=0.56) or Aktthr
308 (p=0.15). Phosphorylation of Akt
at both ser
473 and thr
308 was positively correlated to insulin levels
(p,0.001).We did not detect any changes in total Akt protein
expression as a function of either time or treatment.
AS160 (TBC1D4) and P38
Baseline PAS phosphorylation of AS160 using the phospho-Akt
substrate antibody was comparable on all study days. OGTT
alone induced a significant increase in AS160 PAS phosphoryla-
tion (AU) after 30 min [117613 (baseline) vs. 180622 (30 min),
p=0.013], which was followed by non significant elevated levels at
Figure 3. Hormones and metabolites. (A) Serum levels of insulin,
no significant difference between OGTT and GH+OGTT could be
recorded using ANOVA repeated measurements (p=0.51) or AUCinsulin
(p=0.84). (B) Growth Hormone, (C) FFA, the degree of FFA suppression
was identical throughout the first 120 min between OGTT and GH +
OGTT but the assessed the presence of GH after 120 min caused a
reversal of the insulin suppression of lipolysis which made AUCFFA differ
significantly. Black circles=OGTT + GH, white circles=OGTT, black
triangles=GH. Data are presented as mean 6 SE.
doi:10.1371/journal.pone.0019392.g003
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OGTT+GH induced a more pronounced increase in PAS
phosphorylation of AS160 (AU) which was significant at 30 min,
60 min, and 120 min compared to baseline (OGTT+GH: 94614
(baseline) vs. 191629 (AU) (t=30 min) (p=0.014) vs. 230636
(t=60 min) (p=0.011) vs. 240640 (t=120 min) (p=0.007).
Figure 4. Western blot data. (A) Western blots illustrating comparable levels of phosphorylated insulin signaling proteins (PAS, Aktser
473,
Aktthr
308, P38, pSTAT5, total STAT5 and total Akt). Arrows indicate exposure. Effects of a GH bolus (0.5 mg) and/or an OGTT (75 g) on
phosphorylation of (B) STAT5. GH induced phosphorylation of STAT5 independently of the OGTT (C) Aktser
473, (D) Aktthr
308, (E) AS160, and (F) P38.
Black circles=OGTT + GH, white circles=OGTT, black triangles=GH. Data are presented as mean 6 SE.
doi:10.1371/journal.pone.0019392.g004
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GH+OGTT (p=0.39). GH exposure alone induced a decrease in
PAS phosphorylation of AS160 after 60 min. [88613 (baseline) vs.
66611 (60 min), p=0.049], followed by a return to baseline levels
(Figure 4d). There was a positive correlation between AS160 PAS
phosphorylation and insulin (r=0.86, p,0.000). As regards P38
no significant changes were recorded with time in either
experiment (Figure 4f).
IGF-I and SOCS1–3 mRNA expression
Muscle biopsies taken at 0 min and 120 min were used for the
analysis of IGF-I and SOCS1–3 mRNA expression. No significant
increase in the expression of IGF-I mRNA was observed in any of
the experiments (Table 1). By contrast, GH alone significantly
increased the expression of SOCS-2 mRNA (AU) (p=0.008), and
SOCS-3 mRNA (AU) (p=0.005] compared to baseline. GH +
OGTT significantly increased the expression of SOCS-1 mRNA
(AU) (p=0.03), SOCS-2 mRNA (AU) (p=0.015), and SOCS-3
mRNA (AU) (p=0.038) compared to baseline. There was no
significant expression of SOCS1–3 mRNA when oral glucose was
given alone.
Correlations
To assess the impact of body composition and physical fitness
on GH signaling the percentage of total body fat (%) and lean
body mass (%) were correlated to peak levels of pSTAT5 and
SOCS mRNA expression during the GH-only study. Significant
positive correlations were found between TBF and pSTAT5
(r=0.79, p=0.037), SOCS-2 (r=0.79, p=0.020) and SOCS-
3(r=0.80, p=0.016). Significant negative correlations were found
between LBM and pSTAT5 (r=20.79, p=0.033), SOCS-2
(r=20.79, p=0.019) and SOCS-3(r=20.80, p=0.016), and
between VO2- max/kg and pSTAT5 (r=20.76, p=0.05) and
SOCS-3 m RNA (r=20.73, p=0.04), respectively.
Discussion
It is well documented that GH acutely induces insulin resistance
in human skeletal muscle in vivo [2,19–22], but the underlying
molecular mechanisms remain unknown. In particular - and in
contrast to animal data [12] - studies in human models have not
been able to document an inhibitory effect of GH on insulin
signaling pathways in either muscle or fat [1,13,14,23,24].The
human studies, however, have been conducted either in the basal
state or during a hyperinsulinemic glucose clamp, neither of which
reflects the physiological condition of a meal-induced stimulation
of endogenous insulin secretion and action. In the present study we
therefore exposed healthy subjects to an oral glucose load in the
absence and presence of acute concomitant GH exposure. This
was accompanied by serial muscle biopsies to measure time course
changes in pertinent GH and insulin signaling proteins.
We observed that exposure to a single GH bolus translated into
transient activation of STAT5 signaling in skeletal muscle, which was
uninfluenced by a concomitant oralglucoseload. Conversely,the oral
glucoseload stimulated insulin signaling in skeletal muscle, which was
modified but not abrogated by concomitant GH exposure.
The present study confirms that phosphorylation of STAT5 in
skeletal muscle is a very robust and reproducible effect of systemic
GH exposure in human subjects [13,14,23,25], and it demonstrates
for the first time that activation of STAT5 peaks 60 min after a GH
bolus followedby a declinetowards baselinelevels after120 min. In
support of a physiological role of this response, it is noteworthy that
endogenous GH stimulated by either ghrelin [24] or exercise [26]
also induces pSTAT5 in human skeletal muscle in vivo. It is likely
that the signaling response to an exogenous GH bolus is influenced
by the participant’s pre-study exposure to GH. Recognized
determinants of GH secretion and action in human subjects
include age, gender, body composition and physical fitness [27,28].
We observed a positive correlation between the participants TBF
and GH signaling, whereas both LBM and VO2- max/body weight
correlated negatively with GH signaling. Fat mass is known to be
inversely related to GH secretion (also in normal weight subjects),
whereas the opposite is true for LBM and VO2- max [27,28]. To
reconcile these observations we speculate that pre-study GH levels
may suppress GH signaling induced by an exogenous GH bolus.
This hypothesis obviously needs to be experimentally addressed in
future studies which also should account for other determinants of
GH secretion such as gender and age.
The GH-induced activation of STAT5 was unaffected by a
concomitant oral glucose load, which is in accord with
observations made during a hyperinsulinemic glucose clamp
[13]. It has previously been reported that prolonged (8–24 h)
but not short-term (4 h) insulin pretreatment inhibits GH signaling
via the GHR/JAK2/STAT5B pathway in rat hepatoma cells
[29,30]. Conversely, rapid tyrosine phosphorylation of STAT5 by
insulin has been recorded in a perfused rat liver model [31].
Whether these discrepancies reflect tissue-specific or species-
specific differences remain uncertain, but at present there is no
evidence to support that insulin interacts with GH signaling in
human muscle or fat in vivo.
Table 1. IGF-1 and SOCS 1–3 mRNA.
mRNA Units Event Time/min Median (25%;75%) Test
IGF-I AU OGTT 0 2.41 (0.99;11.5)
AU OGTT 120 1.34 (0.16;9.88) P=0.11
AU GH 0 7.50 (2.05;15.5)
AU GH 120 6.26 (2.38;13.3) P=0.38
AU OGTT+GH 0 10.5 (2.30;25.1)
AU OGTT+GH 120 12.4 (3.02;28.3) P=0.11
SOCS-1 AU OGTT 0 0.55 (0.37;1.66)
AU OGTT 120 1.40 (0.30;1.52) P=1.00
AU GH 0 0.32 (0.12;1.21)
AU GH 120 1.79 (0.55;14.9) P=0.13
AU OGTT+GH 0 0.43 (0.24;0.86)
AU OGTT+GH 120 2.71 (1.16;3.34) P=0.03*
SOCS-2 AU OGTT 0 0.55 (0.50;1.50)
AU OGTT 120 0.83 (0.31;1.98) P=0.56
AU GH 0 1.21 (0.43;1.73)
AU GH 120 3.07 (1.75;3.97) P=0.01*
AU OGTT+GH 0 1.31 (0.39;2.20)
AU OGTT+GH 120 5.26 (2.29;15.2) P=0.02*
SOCS-3 AU OGTT 0 0.67 (0.65;0.99)
AU OGTT 120 2.76 (0.51;3.10) P=0.22
AU GH 0 0.89 (0.52;1.25)
AU GH 120 4.41 (2.02;5.89) P=0.01*
AU OGTT+GH 0 2.06 (0.59;3.87)
AU OGTT+GH 120 4.67 (2.91;15.3) P=0.04*
P-value after Wilcoxon rank sum test.
GH, growth hormone; OGTT,oral glucose tolerance test; AU, arbitrary unit.
doi:10.1371/journal.pone.0019392.t001
Insulin and GH Signaling in Skeletal Muscle
PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e19392We observed that insulin signaling proteins in human skeletal
muscle in vivo are activated in a distinct temporal pattern within
30 min after an OGTT. The serial measurements of insulin
signaling activity during the OGTT allow examination of
temporal physiological changes that may not be detected during
a glucose clamp. Muscle glucose uptake is difficult to quantify
directly during an OGTT. However it has previously been
demonstrated that glucose from an OGTT for the most part is
disposed into skeletal muscle [32]. We therefore consider an
OGTT an acceptable model for studying the impact of GH on
stimulated insulin signaling and glucose uptake in skeletal muscle.
Previous studies in human in vivo models have failed to detect
effects of GH, given as either an infusion [23] or a bolus [13,14],
on insulin signaling via IRS-1 associated PI3-kinase [14,23],
serine/threonine kinase Akt [13,14,23], and Erk1 [13]. This,
together with the present data, deviates from animal as well as in
vitro studies showing that inhibition of the IRS1-Akt pathway is a
mechanism whereby GH induces insulin resistance in skeletal
muscle [12] and fat [33]. Our present data, however, show that
phosphorylation of the intermediary signaling proteins Aktser
473
and Aktthr
308 tended to be delayed (Aktser
473) and suppressed
(Aktthr
308) when GH was given in combination with OGTT,
whereas further downstream phosphorylation of AS160 was more
pronounced when GH was combined with OGTT. Most agree
that phosphorylation of Aktthr
308 occurs prior to phosphorylation
of Aktser473 and that this is a two-step process; based on our data
it is likely that GH may interact with this process. The
physiological significance, however, is unclear when considering
that the activation of AS160, which is downstream of Aktser473,
was activated rather than suppressed by GH. It remains to be
studied whether the latter may reflect an inhibitory effect of GH
on insulin signaling downstream of AS160.
It is well known that GH via STAT5 stimulates SOCS
expression [34] and that SOCS-3 is the major negative regulator
of GH signaling [35–38]. Animal studies suggest that SOCS-1
inhibits insulin-stimulated activation of the Erk1/2 and Akt in vivo,
and phosphorylation of IRS-1 by the IR in vitro [39]. We found
that after 2 hours, GH induced a significant increase in the
expression of both SOCS2 and SOCS3 mRNA expression, and
that GH in combination with OGTT also induced a significant
increase in SOCS1 mRNA. However, none of these changes was
associated with the phosphorylation of Akt. It is also well described
that elevated FFA levels are causally linked to insulin resistance
although the underlying mechanisms are unclear [10,40,41]. In
accordance with this, we have previously observed that experi-
mental suppression of lipolysis in conjunction with GH adminis-
tration in GH-deficient adults significantly abrogates the antago-
nistic effects of GH on insulin-stimulated muscle glucose uptake
[22], and that insulin resistance induced by short-term high dose
GH administration in healthy adults is accompanied by accumu-
lation of fat in muscle cells [42]. But in contrast to data obtained
with intralipid infusion in human subjects, we have not been able
to detect suppression of either PI 3-kinase or Akt/PKB following
GH-induced insulin resistance during a glucose clamp despite a
marked elevation in circulating FFA levels [23]. In the present
study the lipolytic effect of GH was blunted by the concomitant
OGTT, although the degree of suppression was significantly less as
compared to OGTT alone (Figure 3c). Measurement of
intramyocellular lipid content would have strengthened the study
but would have required a separate preparation and thus much
larger biopsies.
Conclusions
We conclude that a physiological GH bolus activates STAT5
signaling pathways acutely in skeletal muscle irrespective of
ambient circulating glucose and insulin levels. The acute
antagonistic effects of GH on glucose-stimulated insulin action
were accompanied by a moderate suppression of Akt activation,
whereas the expression of the more downstream signaling protein
AS160 was amplified rather than suppressed by GH. Our model
provides a viable tool to study GH and insulin action in human
target tissues in vivo.
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